HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis.

Abstract
Tacrolimus hydrate (FK506) reduces myasthenic symptoms due to its immunosuppressive properties. We studied the therapeutic effects of FK506 and noted improvement in 7 of 13 myasthenic patients on the clinical muscle test (myasthenia gravis, MG score). Two other patients with relapsing ocular symptoms improved. We also examined patient sensitivity to FK506, but could not predict such sensitivity before FK506 treatment in the present study.
AuthorsNobuo Wakata, Toyokazu Saito, Sachiko Tanaka, Toshihiko Hirano, Kitaro Oka
JournalClinical neurology and neurosurgery (Clin Neurol Neurosurg) Vol. 106 Issue 1 Pg. 5-8 (Dec 2003) ISSN: 0303-8467 [Print] Netherlands
PMID14643908 (Publication Type: Journal Article)
Chemical References
  • Immunosuppressive Agents
  • Prednisolone
  • Tacrolimus
Topics
  • Adult
  • Aged
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunosuppressive Agents (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Myasthenia Gravis (diagnosis, drug therapy, immunology)
  • Neurologic Examination (drug effects)
  • Patient Selection
  • Prednisolone (therapeutic use)
  • Tacrolimus (adverse effects, therapeutic use)
  • Thymectomy
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: